Pre-made Tarextumab benchmark antibody ( Whole mAb, anti-NOTCH2&3 therapeutic antibody, Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-551-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody
INN Name	Tarextumab
Target	NOTCH2&3
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	OncoMed Pharmaceuticals
Conditions Approved	na
Conditions Active	Pancreatic cancer;Small cell lung cancer
Conditions Discontinued	Solid tumours
Development Tech	MorphoSys HuCAL Phage Display;XmAb Engineering Technology